Effects of soy isoflavones on serum systemic and vascular inflammation markers and oxidative stress in peritoneal dialysis patients: A randomized controlled trial

Cardiovascular disease (CVD) is common in peritoneal dialysis (PD) patients. This study was designed to investigate the effects of isoflavones on systemic and vascular inflammation markers and oxidative stress in PD patients. In this randomized clinical trial, 40 PD patients were randomly assigned t...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2020-11, Vol.34 (11), p.3011-3018
Main Authors: Yari, Zahra, Tabibi, Hadi, Najafi, Iraj, Hedayati, Mehdi, Movahedian, Mina
Format: Article
Language:English
Subjects:
Adhesion
Biomarkers - blood
Cardiovascular diseases
Cell adhesion
Cell adhesion & migration
Cell adhesion molecules
Clinical trials
Dialysis
Double-Blind Method
Female
Heart diseases
Humans
Inflammation - blood
Isoflavones
Isoflavones - pharmacology
Isoflavones - therapeutic use
Male
Malondialdehyde
Markers
Middle Aged
Oxidative stress
Peritoneal dialysis
Peritoneal Dialysis - methods
Peritoneum
Risk analysis
Risk factors
soy isoflavones
systemic inflammation
vascular inflammation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease (CVD) is common in peritoneal dialysis (PD) patients. This study was designed to investigate the effects of isoflavones on systemic and vascular inflammation markers and oxidative stress in PD patients. In this randomized clinical trial, 40 PD patients were randomly assigned to either the isoflavone or the placebo group. The isoflavone group received 100 mg soy isoflavones daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of eighth week, serum high sensitive C‐reactive protein (hs‐CRP), intercellular adhesion molecule type 1 (ICAM‐1), vascular cell adhesion molecule type 1 (VCAM‐1), E‐selectin, and malondialdehyde were measured. Serum VCAM‐1 decreased significantly in the isoflavone group at the end of Week 8 compared to baseline (p = .01), whereas no significant change was observed in the placebo group. Serum ICAM‐1 decreased significantly in the isoflavone (p = .01) and placebo (p = .01) group compared to baseline. However, the reduction of ICAM‐1 was significantly higher in the isoflavone group than in the placebo group (p = .02). There were no significant differences between the two groups in mean changes of serum E‐selectin, malondialdehyde, and hs‐CRP. This study indicates that isoflavones reduce serum VCAM‐1 and ICAM‐1, which are two CVD risk factors, in PD patients.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.6729